This week’s Reefer Report Card exposes Congress’s hollow promises to vets, New York’s zoning mess, a $10M Michigan grow raid, and DEA raids while rescheduling stalls. We grade the chaos, call out the hypocrisy, and show why cannabis reform still spins in circles.
Tyson’s Throwing Haymakers at Federal Weed Laws
Mike Tyson just launched a full-court press on the federal weed system. Joined by athletes and artists, he’s demanding President Trump reschedule cannabis, release prisoners, and stop treating legal operators like criminals. The DEA is stalling. Congress is hiding. The champ is not. This is the culture punching back, one haymaker at a time.
High on Religion: Why Churches Are Starting to Embrace Cannabis
Church and cannabis are joining forces in a growing number of spiritual communities across the U.S., testing the limits of religious freedom and federal weed laws. From Elevationists in Colorado to sacred smoke ceremonies in Michigan, Pot Culture investigates the rising spiritual movement to make cannabis a sacrament.
DEA Stalls on Cannabis Rescheduling: What’s the Hold-Up?
The DEA is dragging its feet on cannabis rescheduling despite over 43,000 public comments and a formal Schedule III recommendation from HHS. What’s the hold-up? This deep-dive exposes the legal limbo, political stall tactics, and why America’s weed policy is still frozen in time.
BREAKING: DEA Reclassifies Marijuana as a Vegetable
In a bizarre twist of bureaucratic brilliance, the DEA has reclassified marijuana as a leafy green vegetable—officially adding it to the American food pyramid. From salad bowls to school lunches, the War on Drugs just got edible. Satirical? Yes. Unbelievable? Barely.
The DEA’s Stance on Rescheduling: Progress or Stalemate?
The DEA is delaying the rescheduling of marijuana from Schedule I, despite overwhelming scientific support and recommendations from health authorities. This stalling harms the cannabis industry, patients, and communities affected by marijuana criminalization. Political influences from big pharmaceutical companies contribute to this resistance, prolonging the adverse effects of current drug policies.